The Alzheimer’s disease diagnostic market is expanding as ageing populations, rising dementia prevalence, greater awareness, and advances in biomarkers and imaging increase the need for earlier and more accurate assessment. The market was valued at USD 10.26 billion in 2024 and is projected to reach USD 26.64 billion by 2035, growing at a CAGR of 9.02%.

Alzheimer’s disease is the most common form of dementia and is associated with progressive cognitive decline. Early assessment can help patients, families, and healthcare providers understand symptoms, plan care, access support, and consider appropriate clinical pathways.

Cognitive assessment is the largest application segment, accounting for approximately 38% of market demand. Cognitive tests remain widely used because they are relatively accessible and can provide an initial assessment of memory, reasoning, attention, and daily functioning.

Neuroimaging is the fastest-growing segment. MRI, PET, CT, and other imaging technologies can help clinicians evaluate brain structure, metabolic activity, and disease-related patterns. These tools are becoming more important as new diagnostic frameworks emphasize biological and imaging evidence alongside clinical assessment.

Biomarker testing and genetic testing are also gaining attention. Blood-based biomarkers, cerebrospinal-fluid analysis, and genetic markers may support research and early detection, although availability, cost, clinical interpretation, and regulatory guidance vary by region.

Hospitals are the largest end users because they provide integrated neurologic care, imaging, laboratory testing, and specialist consultation. Diagnostic centers and clinics are expected to grow as testing becomes more accessible.

Read more: Alzheimer’s Disease Diagnostic Market 1017

FAQs

Q1. Which diagnostic segment leads the Alzheimer’s market?
Cognitive assessment leads because it is widely used for initial evaluation of cognitive changes.

Q2. Why is neuroimaging growing quickly?
It can provide more detailed information about brain structure and disease-related patterns.

Tags: Alzheimer’s diagnostics, cognitive assessment, neuroimaging, dementia care, biomarker testing